Guotai CSI BIOMEDICINE ETF(512290) Rises 3.86% in Morning Trading, Sees Net Inflow of 42.1030 Million Yuan Over the Past 10 Trading Days

NewTimeSpace News, as of 09:38 on April 28, 2026, Guotai Biopharmaceutical ETF (512290) rose 3.86%, with its latest quoted price at 1 yuan. Looking at a longer timeframe, as of April 27, 2026, Guotai Biopharmaceutical ETF gained 6.91% over the past year. (The stocks listed above are merely index constituents and do not constitute any specific recommendation.)

In terms of liquidity, Guotai Biopharmaceutical ETF recorded an intraday turnover rate of 1.69%, with a trading volume of 64.4425 million yuan. Over a longer horizon, as of April 27, the ETF's average daily turnover over the past month stood at 89.4932 million yuan.

Regarding scale, the latest AUM of Guotai Biopharmaceutical ETF reached 3.632 billion yuan. (Data source: Wind)

In terms of capital inflows, the latest capital inflow and outflow for Guotai Biopharmaceutical ETF were flat. Looking at a longer timeframe, over the past ten trading days, the total net inflow amounted to 42.1030 million yuan. (Data source: Wind)

Data shows that leveraged funds continue to position themselves. The net margin purchase amount for Guotai Biopharmaceutical ETF on the previous trading day reached 1.1420 million yuan, and the latest margin balance stood at 141 million yuan. (Data source: Wind)

As of April 27, Guotai Biopharmaceutical ETF's net value increased by 6.87% over the past year. In terms of return capability, as of April 27, 2026, since its inception, the ETF achieved a highest single-month return of 23.26%, a longest consecutive gaining streak of eight months with a cumulative gain of 109.28%, and an average return of 6.56% during up months. As of April 27, 2026, since its inception, the ETF's annualized excess return over its benchmark was 2.50%.

In terms of drawdown, as of April 27, 2026, Guotai Biopharmaceutical ETF's relative drawdown versus its benchmark since the beginning of the year was 0.11%.

In terms of fees, Guotai Biopharmaceutical ETF has a management fee rate of 0.50% and a custody fee rate of 0.10%.

In terms of tracking accuracy, as of April 27, 2026, Guotai Biopharmaceutical ETF's tracking error since the beginning of the year was 0.008%.

From a valuation perspective, the latest price-to-earnings ratio (PE-TTM) of the CSI Biopharmaceutical Index, which Guotai Biopharmaceutical ETF tracks, is only 39.4 times, placing it at the 8.98th percentile over the past year—meaning the valuation is lower than that of over 91.02% of the time in the past year, indicating a historically low level.

Guotai Biopharmaceutical ETF closely tracks the CSI Biopharmaceutical Index. The CSI Biopharmaceutical Index selects listed company securities that provide products and services such as cell therapy, gene sequencing, blood products, biotech drugs, vaccines, and in vitro diagnostics as index constituents, in order to reflect the overall performance of listed company securities in the biopharmaceutical sector.

NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.